{
    "componentChunkName": "component---src-templates-article-page-tsx",
    "path": "/articles/use-case-agent-ad",
    "result": {"data":{"contentfulArticlePage":{"blocksAfter":[{"__typename":"ContentfulCtaBlock","backgroundImage":null,"backgroundOverlay":true,"body":{"raw":"{\"data\":{},\"content\":[{\"data\":{},\"content\":[{\"data\":{},\"marks\":[],\"value\":\"We're ready to support you in your biomedical research efforts. Contact us now and we'll be in touch with you at the earliest opportunity.\",\"nodeType\":\"text\"}],\"nodeType\":\"paragraph\"}],\"nodeType\":\"document\"}","references":[]},"callToActionCaption":"Send","callToActionTarget":null,"callToActionType":"Form","formName":"fingenious-contact","formOptions":["Early Discovery","Pre-Approval R&D","Post-Approval","Samples","Data","Study Participants"],"formOptionsSelection":"Checkbox","formOptionsTranslationKey":"areaOfInterest","htmlElementId":"contact-us-form-fingenious","id":"f48f85e9-6a56-522d-85fd-25b711028181","theme":"light","title":"Contact us"}],"blocksBefore":null,"body":{"raw":"{\"nodeType\":\"document\",\"data\":{},\"content\":[{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"Paris, FRANCE – 9 June 2026\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"Neurodegenerative diseases begin years before symptoms become visible. With the goal of bringing precision medicine to neurodegenerative diseases, \",\"marks\":[],\"data\":{}},{\"nodeType\":\"hyperlink\",\"data\":{\"uri\":\"https://www.agent-biotech.com/\"},\"content\":[{\"nodeType\":\"text\",\"value\":\"AgenT\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}}]},{\"nodeType\":\"text\",\"value\":\" \",\"marks\":[{\"type\":\"bold\"}],\"data\":{}},{\"nodeType\":\"text\",\"value\":\"develops solutions that enable earlier detection, patient stratification, and the development of more effective interventions. Their science is based on combining blood-based multiomics, machine learning, and longitudinal clinical data to reveal biological patterns before symptoms become irreversible.\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"AgenT’s biomarker discovery strategy originated from a proprietary translational rat model of Alzheimer’s disease that reproduces key pathological and clinical features of the human disease (Audrain et al., 2018). This model enabled the identification of multiomics biomarker signatures associated with disease progression, which were subsequently translated and validated in human cohorts. \",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"Building on this work, AgenT is developing two blood tests, B-HEALED\",\"marks\":[],\"data\":{}},{\"nodeType\":\"embedded-entry-inline\",\"data\":{\"target\":{\"sys\":{\"id\":\"4nqve1j1TBLPt1T9IJYtmj\",\"type\":\"Link\",\"linkType\":\"Entry\"}}},\"content\":[]},{\"nodeType\":\"text\",\"value\":\" and B-AHEAD\",\"marks\":[],\"data\":{}},{\"nodeType\":\"embedded-entry-inline\",\"data\":{\"target\":{\"sys\":{\"id\":\"4nqve1j1TBLPt1T9IJYtmj\",\"type\":\"Link\",\"linkType\":\"Entry\"}}},\"content\":[]},{\"nodeType\":\"text\",\"value\":\", designed to predict progression to Alzheimer’s dementia symptoms. In a first multicenter retrospective study involving 632 individuals, B-HEALED\",\"marks\":[],\"data\":{}},{\"nodeType\":\"embedded-entry-inline\",\"data\":{\"target\":{\"sys\":{\"id\":\"4nqve1j1TBLPt1T9IJYtmj\",\"type\":\"Link\",\"linkType\":\"Entry\"}}},\"content\":[]},{\"nodeType\":\"text\",\"value\":\" successfully identified Mild Cognitive Impairment (MCI) patients who later progressed to Alzheimer’s dementia, while B-AHEAD\",\"marks\":[],\"data\":{}},{\"nodeType\":\"embedded-entry-inline\",\"data\":{\"target\":{\"sys\":{\"id\":\"4nqve1j1TBLPt1T9IJYtmj\",\"type\":\"Link\",\"linkType\":\"Entry\"}}},\"content\":[]},{\"nodeType\":\"text\",\"value\":\" identified cognitively normal individuals who subsequently developed the disease (Souchet et al., 2024).\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"By integrating multiple biomarkers through machine learning, these tests capture the biological complexity of AD, offering a more specific and clinically meaningful diagnostic tool that can transform early detection and intervention.\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"AgenT collaborates with Finnish Biobanks to quantify multi-omics biomarkers in biobanked plasma samples as part of a global validation effort for next-generation versions of B-HEALED and B-AHEAD across 20 cohorts and more than 4,000 participants.\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"Agent’s collaboration with Finnish Biobanks includes both plasma samples and detailed clinical data essential to the study from Auria Biobank and Biobank of Eastern Finland. The process was supported end-to-end by FINBB and its digital Fingenious\",\"marks\":[],\"data\":{}},{\"nodeType\":\"embedded-entry-inline\",\"data\":{\"target\":{\"sys\":{\"id\":\"2ImHFmGMq1zTimvPNVYVsx\",\"type\":\"Link\",\"linkType\":\"Entry\"}}},\"content\":[]},{\"nodeType\":\"text\",\"value\":\" service, starting from consultation and the feasibility assessment to accessing biobank collections. \",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"“Working with the Finnish Biobanks has been an outstanding experience, marked by trust, clear communication, and seamless support at every stage. Their cohorts provide an exceptional opportunity to study real-world populations, including the rare chance to follow individuals from healthy aging to the onset of neurodegenerative diseases such as Alzheimer’s”,\",\"marks\":[{\"type\":\"italic\"}],\"data\":{}},{\"nodeType\":\"text\",\"value\":\" says \",\"marks\":[],\"data\":{}},{\"nodeType\":\"text\",\"value\":\"Benoît Souchet\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}},{\"nodeType\":\"text\",\"value\":\", the Chief Scientific Officer of AgenT.\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"“Public-private partnership with AI focused innovative companies like AgenT is crucial for Finnish Biobanks. We are happy that our longitudinal data combined with high quality samples are suitable for developing new diagnostic tools and that this unique research cooperation can speed up the transfer of new findings from research to patient care”\",\"marks\":[{\"type\":\"italic\"}],\"data\":{}},{\"nodeType\":\"text\",\"value\":\", says \",\"marks\":[],\"data\":{}},{\"nodeType\":\"text\",\"value\":\"Johanna Mäkelä\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}},{\"nodeType\":\"text\",\"value\":\", FINBB’s Director of Research and Services.\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"About FINBB and its Fingenious\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}},{\"nodeType\":\"embedded-entry-inline\",\"data\":{\"target\":{\"sys\":{\"id\":\"2ImHFmGMq1zTimvPNVYVsx\",\"type\":\"Link\",\"linkType\":\"Entry\"}}},\"content\":[]},{\"nodeType\":\"text\",\"value\":\" service\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"\",\"marks\":[],\"data\":{}},{\"nodeType\":\"hyperlink\",\"data\":{\"uri\":\"https://finbb.fi/en/\"},\"content\":[{\"nodeType\":\"text\",\"value\":\"Finnish Biobank Cooperative – FINBB\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}}]},{\"nodeType\":\"text\",\"value\":\" \",\"marks\":[{\"type\":\"bold\"}],\"data\":{}},{\"nodeType\":\"text\",\"value\":\"is a biobank cooperative owned by five wellbeing services counties, HUS, six major universities in Finland, and the Finnish Institute for Health and Welfare (THL). FINBB has eight member biobanks. FINBB is the national coordinator in the Finnish biobank network and plays a key role in building an internationally advanced biobank infrastructure. FINBB’s Fingenious\",\"marks\":[],\"data\":{}},{\"nodeType\":\"embedded-entry-inline\",\"data\":{\"target\":{\"sys\":{\"id\":\"2ImHFmGMq1zTimvPNVYVsx\",\"type\":\"Link\",\"linkType\":\"Entry\"}}},\"content\":[]},{\"nodeType\":\"text\",\"value\":\" service is the digital gateway to Finnish biobanks and biomedical research, providing researchers with access to high-quality biobank samples, data, cohorts, and study participant finding. FINBB is a partner in \",\"marks\":[],\"data\":{}},{\"nodeType\":\"hyperlink\",\"data\":{\"uri\":\"https://healthhubfinland.eu/fi/healthhub-finland-edih/\"},\"content\":[{\"nodeType\":\"text\",\"value\":\"HealthHub Finland EDIH\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"text\",\"value\":\" – European Digital Innovation Hub.\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"About AgenT\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"\",\"marks\":[],\"data\":{}},{\"nodeType\":\"hyperlink\",\"data\":{\"uri\":\"https://www.agent-biotech.com/\"},\"content\":[{\"nodeType\":\"text\",\"value\":\"AgenT\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}}]},{\"nodeType\":\"text\",\"value\":\" \",\"marks\":[{\"type\":\"bold\"}],\"data\":{}},{\"nodeType\":\"text\",\"value\":\" is a French healthtech company pioneering blood-based precision medicine for neurodegenerative diseases. By combining targeted proteomics, metabolomics and AI, AgenT moves beyond single-biomarker approaches to capture a deeper view of disease biology, progression risk and treatment-relevant pathways.\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"Its first platform, HORIZON\",\"marks\":[],\"data\":{}},{\"nodeType\":\"embedded-entry-inline\",\"data\":{\"target\":{\"sys\":{\"id\":\"4nqve1j1TBLPt1T9IJYtmj\",\"type\":\"Link\",\"linkType\":\"Entry\"}}},\"content\":[]},{\"nodeType\":\"text\",\"value\":\", monitors 8 key biological pathways through the quantification of 85 proteins and metabolites, helping pharma and biotech companies improve patient stratification, biological monitoring and CNS clinical trial decision-making. Building on this platform, AgenT is developing predictive blood-based algorithms to identify individuals at risk of progressing to Alzheimer’s dementia symptoms.\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"AgenT’s mission is to bring earlier, more precise and more actionable tools to brain health, supporting the next generation of diagnostics and therapies for neurodegenerative diseases.\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"More information:\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"Johanna Mäkelä\\nFINBB, Director of Research and Services\\njohanna.makela@finbb.fi\\n\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"Benoît Souchet\\nAgenT, Chief Scientific Officer\\nbenoit.souchet@agent-biotech.com\\n\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"References:\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"M. Audrain, B. Souchet, S. Alves, R. Fol, A. Viode, A. Haddjeri, \",\"marks\":[],\"data\":{}},{\"nodeType\":\"text\",\"value\":\"et al.  \",\"marks\":[{\"type\":\"italic\"}],\"data\":{}},{\"nodeType\":\"text\",\"value\":\"betaAPP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimer's Disease. Cereb Cortex, 28 (11) (2018), pp. 3976-3993\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"B. Souchet, A. Michaïl, M. Heuillet, A. Dupuy-Gayral, E. Haudebourg, C. Pech, \",\"marks\":[],\"data\":{}},{\"nodeType\":\"text\",\"value\":\"et al.  \",\"marks\":[{\"type\":\"italic\"}],\"data\":{}},{\"nodeType\":\"text\",\"value\":\"Multiomics blood-based biomarkers predict Alzheimer's predementia with high specificity in a multicentric cohort study.  J Prev Alzheimers Dis, 11 (2024), pp. 567-581\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"Other:\",\"marks\":[{\"type\":\"bold\"}],\"data\":{}}]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"As a partner of HealthHub Finland EDIH, FINBB's contribution in the collaboration has been supported by the European Union.\",\"marks\":[],\"data\":{}}]},{\"nodeType\":\"embedded-asset-block\",\"data\":{\"target\":{\"sys\":{\"id\":\"1j7byOoyMO7e8RZv0JAmOC\",\"type\":\"Link\",\"linkType\":\"Asset\"}}},\"content\":[]},{\"nodeType\":\"paragraph\",\"data\":{},\"content\":[{\"nodeType\":\"text\",\"value\":\"\",\"marks\":[],\"data\":{}}]}]}","references":[{"__typename":"ContentfulSuperscriptInline","contentful_id":"4nqve1j1TBLPt1T9IJYtmj","text":"TM"},{"__typename":"ContentfulSuperscriptInline","contentful_id":"2ImHFmGMq1zTimvPNVYVsx","text":"®"},{"__typename":"ContentfulAsset","gatsbyImageData":{"images":{"sources":[{"srcSet":"//images.ctfassets.net/7e3gy8pq6aym/1j7byOoyMO7e8RZv0JAmOC/6b1099c8a0086eed13caa8b37e2855ba/Vaaditut_logot_verkkosivuille.png?w=640&h=418&q=50&fm=webp 640w,\n//images.ctfassets.net/7e3gy8pq6aym/1j7byOoyMO7e8RZv0JAmOC/6b1099c8a0086eed13caa8b37e2855ba/Vaaditut_logot_verkkosivuille.png?w=1280&h=835&q=50&fm=webp 1280w,\n//images.ctfassets.net/7e3gy8pq6aym/1j7byOoyMO7e8RZv0JAmOC/6b1099c8a0086eed13caa8b37e2855ba/Vaaditut_logot_verkkosivuille.png?w=2560&h=1670&q=50&fm=webp 2560w,\n//images.ctfassets.net/7e3gy8pq6aym/1j7byOoyMO7e8RZv0JAmOC/6b1099c8a0086eed13caa8b37e2855ba/Vaaditut_logot_verkkosivuille.png?w=4000&h=2609&q=50&fm=webp 4000w","sizes":"(min-width: 2560px) 2560px, 100vw","type":"image/webp"}],"fallback":{"src":"//images.ctfassets.net/7e3gy8pq6aym/1j7byOoyMO7e8RZv0JAmOC/6b1099c8a0086eed13caa8b37e2855ba/Vaaditut_logot_verkkosivuille.png?w=2560&h=1670&q=50&fm=png","srcSet":"//images.ctfassets.net/7e3gy8pq6aym/1j7byOoyMO7e8RZv0JAmOC/6b1099c8a0086eed13caa8b37e2855ba/Vaaditut_logot_verkkosivuille.png?w=640&h=418&q=50&fm=png 640w,\n//images.ctfassets.net/7e3gy8pq6aym/1j7byOoyMO7e8RZv0JAmOC/6b1099c8a0086eed13caa8b37e2855ba/Vaaditut_logot_verkkosivuille.png?w=1280&h=835&q=50&fm=png 1280w,\n//images.ctfassets.net/7e3gy8pq6aym/1j7byOoyMO7e8RZv0JAmOC/6b1099c8a0086eed13caa8b37e2855ba/Vaaditut_logot_verkkosivuille.png?w=2560&h=1670&q=50&fm=png 2560w,\n//images.ctfassets.net/7e3gy8pq6aym/1j7byOoyMO7e8RZv0JAmOC/6b1099c8a0086eed13caa8b37e2855ba/Vaaditut_logot_verkkosivuille.png?w=4000&h=2609&q=50&fm=png 4000w","sizes":"(min-width: 2560px) 2560px, 100vw"}},"layout":"constrained","backgroundColor":"#f8f8f8","width":2560,"height":1670},"file":{"contentType":"image/png","url":"//images.ctfassets.net/7e3gy8pq6aym/1j7byOoyMO7e8RZv0JAmOC/6b1099c8a0086eed13caa8b37e2855ba/Vaaditut_logot_verkkosivuille.png"},"contentful_id":"1j7byOoyMO7e8RZv0JAmOC","title":"EU logo EDIH"}]},"fields":{"route":"/articles/use-case-agent-ad"},"fullTitle":"AgenT Collaboration with Finnish Biobanks Promotes Early Detection in Alzheimer’s Disease","metaDescription":{"metaDescription":"Neurodegenerative diseases begin years before symptoms become visible. With the goal of bringing precision medicine to neurodegenerative diseases, AgenT develops solutions that enable earlier detection, patient stratification, and the development of more effective interventions. AgenT collaborates with Finnish Biobanks to quantify multi-omics biomarkers in biobanked plasma samples as part of a global validation effort for two blood tests that AgenT is developing to advance early detection in Alzheimer's."},"metaImage":{"file":{"url":"//images.ctfassets.net/7e3gy8pq6aym/3e3ptP0htK3k0gpZVAujQ6/bf35429abcacb54f559c2121215fd22b/Fingenious_Kuvituskuva_Yhdistelma_laborantti_metsa.jpg"},"gatsbyImageData":{"images":{"sources":[{"srcSet":"//images.ctfassets.net/7e3gy8pq6aym/3e3ptP0htK3k0gpZVAujQ6/bf35429abcacb54f559c2121215fd22b/Fingenious_Kuvituskuva_Yhdistelma_laborantti_metsa.jpg?w=480&h=320&q=50&fm=webp 480w,\n//images.ctfassets.net/7e3gy8pq6aym/3e3ptP0htK3k0gpZVAujQ6/bf35429abcacb54f559c2121215fd22b/Fingenious_Kuvituskuva_Yhdistelma_laborantti_metsa.jpg?w=960&h=640&q=50&fm=webp 960w,\n//images.ctfassets.net/7e3gy8pq6aym/3e3ptP0htK3k0gpZVAujQ6/bf35429abcacb54f559c2121215fd22b/Fingenious_Kuvituskuva_Yhdistelma_laborantti_metsa.jpg?w=1920&h=1280&q=50&fm=webp 1920w","sizes":"(min-width: 1920px) 1920px, 100vw","type":"image/webp"}],"fallback":{"src":"//images.ctfassets.net/7e3gy8pq6aym/3e3ptP0htK3k0gpZVAujQ6/bf35429abcacb54f559c2121215fd22b/Fingenious_Kuvituskuva_Yhdistelma_laborantti_metsa.jpg?w=1920&h=1280&fl=progressive&q=50&fm=jpg","srcSet":"//images.ctfassets.net/7e3gy8pq6aym/3e3ptP0htK3k0gpZVAujQ6/bf35429abcacb54f559c2121215fd22b/Fingenious_Kuvituskuva_Yhdistelma_laborantti_metsa.jpg?w=480&h=320&fl=progressive&q=50&fm=jpg 480w,\n//images.ctfassets.net/7e3gy8pq6aym/3e3ptP0htK3k0gpZVAujQ6/bf35429abcacb54f559c2121215fd22b/Fingenious_Kuvituskuva_Yhdistelma_laborantti_metsa.jpg?w=960&h=640&fl=progressive&q=50&fm=jpg 960w,\n//images.ctfassets.net/7e3gy8pq6aym/3e3ptP0htK3k0gpZVAujQ6/bf35429abcacb54f559c2121215fd22b/Fingenious_Kuvituskuva_Yhdistelma_laborantti_metsa.jpg?w=1920&h=1280&fl=progressive&q=50&fm=jpg 1920w","sizes":"(min-width: 1920px) 1920px, 100vw"}},"layout":"constrained","backgroundColor":"#f8f8f8","width":2560,"height":1707}},"metaTitle":"AgenT Collaboration with Finnish Biobanks Promotes Early Detection in Alzheimer’s Disease","parentPage":{"fields":{"route":"/use-cases"},"menuTitle":"Use cases"},"publishedAt":"Jun 9, 2026"}},"pageContext":{"slug":"fingenious/use-case-agent-ad","language":"en","intl":{"language":"en","languages":["en"],"messages":{"supportedLanguages.en":"EN","supportedLanguages.fi":"FI","authentication.login":"Login","form.areaOfInterest":"Area of interest","form.body":"Your message","form.consent":"I agree to","form.discovery":"How did you find us?","form.email":"Email","form.name":"Your name","form.organization":"Company or organization","form.policy":"privacy policy","form.required":"Required field","form.success.body":"Our team will contact you soon.","form.success.heading":"We have received your message—thank you for reaching out!","form.topic":"Select topic"},"routed":false,"originalPath":"/articles/use-case-agent-ad","redirect":true,"defaultLanguage":"en"},"locale":"en-US"}},
    "staticQueryHashes": ["1648719659","3130670927","3243898050","3265115003","3728338000","471647045","841752961"]}